O	0	10	Prevention
O	11	13	of
B-condition	14	18	post
I-condition	18	19	-
I-condition	19	29	mastectomy
I-condition	30	41	neuropathic
I-condition	42	46	pain
O	47	51	with
B-intervention	52	61	memantine
O	61	62	:
O	63	68	study
O	69	77	protocol
O	78	81	for
O	82	83	a
O	84	94	randomized
O	95	105	controlled
O	106	111	trial
O	111	112	.

O	113	114	N
O	114	115	-
O	115	121	methyl
O	121	122	-
O	122	123	D
O	123	124	-
O	124	133	aspartate
O	134	142	receptor
O	143	154	antagonists
O	155	158	are
O	159	168	potential
O	169	178	therapies
O	179	182	for
O	183	194	neuropathic
O	195	199	pain
O	199	200	,
O	201	204	and
O	205	214	memantine
O	215	218	has
O	219	220	a
O	221	225	good
O	226	235	tolerance
O	236	243	profile
O	243	244	.

O	245	246	A
O	247	258	preclinical
O	259	264	study
O	265	273	recently
O	274	282	reported
O	283	287	that
O	288	298	presurgery
O	299	308	memantine
O	309	312	may
O	313	320	prevent
O	321	332	neuropathic
O	333	337	pain
O	338	349	development
O	350	353	and
O	354	363	cognition
O	364	375	dysfunction
O	375	376	.

O	377	388	Considering
O	389	392	the
O	393	397	high
O	398	408	prevalence
O	409	411	of
O	412	418	breast
O	419	425	cancer
O	426	429	and
O	430	432	of
O	433	437	post
O	437	438	-
O	438	448	mastectomy
O	449	460	neuropathic
O	461	465	pain
O	465	466	,
O	467	468	a
O	469	477	clinical
O	478	483	trial
O	484	486	is
O	487	494	carried
O	495	498	out
O	499	501	to
O	502	510	evaluate
O	511	513	if
O	514	523	memantine
O	524	527	may
O	528	535	prevent
O	536	547	neuropathic
O	548	552	pain
O	553	564	development
O	565	568	and
O	569	577	maintain
O	578	587	cognitive
O	588	596	function
O	597	600	and
O	601	608	quality
O	609	611	of
O	612	616	life
O	617	619	in
O	620	626	cancer
O	627	635	patients
O	635	636	.

O	637	638	A
O	639	649	randomized
O	650	658	clinical
O	659	664	trial
O	665	666	(
O	666	677	NCT01536314
O	677	678	)
O	679	687	includes
B-total-participants	688	690	40
B-eligibility	691	696	women
I-eligibility	697	701	with
I-eligibility	702	708	breast
I-eligibility	709	715	cancer
I-eligibility	716	726	undergoing
I-eligibility	727	737	mastectomy
O	738	740	at
O	741	744	the
O	745	753	Oncology
O	754	762	Hospital
O	762	763	,
B-location	764	772	Clermont
I-location	772	773	-
I-location	773	780	Ferrand
I-location	780	781	,
I-location	782	788	France
O	788	789	.

O	790	799	Memantine
O	800	801	(
O	801	802	5
O	803	805	to
O	806	808	20
O	809	811	mg
O	811	812	/
O	812	815	day
O	815	816	;
O	817	818	n
O	819	820	=
B-intervention-participants	821	823	20
O	823	824	)
O	825	827	or
B-control	828	835	placebo
O	836	837	(
O	837	838	n
O	839	840	=
B-control-participants	841	843	20
O	843	844	)
O	845	847	is
O	848	860	administered
O	861	864	for
O	865	866	4
O	867	872	weeks
O	873	881	starting
O	882	883	2
O	884	889	weeks
O	890	896	before
O	897	904	surgery
O	904	905	.

O	906	915	Intensity
O	916	918	of
O	919	923	pain
O	923	924	,
O	925	934	cognitive
O	935	943	function
O	943	944	,
O	945	952	quality
O	953	955	of
O	956	960	life
O	961	964	and
O	965	967	of
O	968	973	sleep
O	973	974	,
O	975	982	anxiety
O	983	986	and
O	987	997	depression
O	998	1001	are
O	1002	1011	evaluated
O	1012	1016	with
O	1017	1031	questionnaires
O	1031	1032	.

O	1033	1036	The
O	1037	1044	primary
O	1045	1053	endpoint
O	1054	1056	is
B-outcome-Measure	1057	1061	pain
I-outcome-Measure	1062	1071	intensity
O	1072	1074	on
O	1075	1076	a
O	1077	1078	0
O	1079	1081	to
O	1082	1084	10
O	1084	1085	)
O	1086	1095	numerical
O	1096	1101	scale
O	1102	1104	at
O	1105	1106	3
O	1107	1113	months
O	1114	1118	post
O	1118	1119	-
O	1119	1129	mastectomy
O	1129	1130	.

O	1131	1135	Data
O	1136	1144	analysis
O	1145	1147	is
O	1148	1157	performed
O	1158	1163	using
O	1164	1169	mixed
O	1170	1176	models
O	1177	1180	and
O	1181	1184	the
O	1185	1190	tests
O	1191	1194	are
O	1195	1198	two
O	1198	1199	-
O	1199	1204	sided
O	1204	1205	,
O	1206	1210	with
O	1211	1212	a
O	1213	1217	type
O	1218	1219	I
O	1220	1225	error
O	1226	1229	set
O	1230	1232	at
O	1233	1234	Î±
O	1235	1236	=
O	1237	1238	0
O	1238	1239	.
O	1239	1241	05
O	1241	1242	.

O	1243	1246	The
O	1247	1257	hypothesis
O	1258	1260	of
O	1261	1265	this
O	1266	1279	translational
O	1280	1288	approach
O	1289	1291	is
O	1292	1294	to
O	1295	1302	confirm
O	1303	1305	in
O	1306	1314	patients
O	1315	1318	the
O	1319	1329	beneficial
O	1330	1342	prophylactic
O	1343	1349	effect
O	1350	1352	of
O	1353	1362	memantine
O	1363	1371	observed
O	1372	1374	in
O	1375	1382	animals
O	1382	1383	.

O	1384	1388	Such
O	1389	1390	a
O	1391	1401	protective
O	1402	1408	action
O	1409	1411	of
O	1412	1421	memantine
O	1422	1429	against
O	1430	1441	neuropathic
O	1442	1446	pain
O	1447	1450	and
O	1451	1460	cognitive
O	1461	1472	dysfunction
O	1473	1478	would
O	1479	1486	greatly
O	1487	1494	improve
O	1495	1498	the
O	1499	1506	quality
O	1507	1509	of
O	1510	1514	life
O	1515	1517	of
O	1518	1524	cancer
O	1525	1533	patients
O	1533	1534	.

O	1535	1549	ClinicalTrials
O	1549	1550	.
O	1550	1553	gov
O	1553	1554	:
O	1555	1566	NCT01536314
O	1567	1569	on
O	1570	1572	16
O	1573	1581	February
O	1582	1586	2012
O	1586	1587	.
